Ali R Jazirehi

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc Therapeutic implications of targeting the PI3Kinase/AKT/mTOR signaling module in melanoma therapy
    Ali R Jazirehi
    Department of Surgery, Division of Surgical Oncology, and The Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, University of California at Los Angeles Los Angeles, CA, USA
    Am J Cancer Res 2:178-91. 2012
  2. pmc Proteasome inhibition blocks NF-κB and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLs
    Ali R Jazirehi
    Department of Surgery and the Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, University of California at Los Angeles, Los Angeles, CA 90095, USA
    Mol Cancer Ther 11:1332-41. 2012
  3. ncbi request reprint Novel approaches to modulate apoptosis resistance: basic and clinical implications in the treatment of chronic lymphocytic leukemia (CLL)
    Aisha Masood
    The Tisch Cancer Institute, Bone Marrow Transplant, Mount Sinai School of Medicine, NY, NY 10029, USA
    Curr Drug Deliv 9:30-40. 2012
  4. doi request reprint Development of rituximab-resistant B-NHL clones: an in vitro model for studying tumor resistance to monoclonal antibody-mediated immunotherapy
    Ali R Jazirehi
    Department of Surgery, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
    Methods Mol Biol 731:407-19. 2011
  5. doi request reprint Molecular mechanism of MART-1+/A*0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interaction
    Ali R Jazirehi
    Department of Surgery, Molecular and Medical Pharmacology, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, California, USA
    Cancer Res 71:1406-17. 2011
  6. doi request reprint Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy
    Ali R Jazirehi
    Department of Surgery, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, California, USA
    Anticancer Drugs 21:805-13. 2010
  7. doi request reprint The NF-kappaB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs
    Mario I Vega
    Department of Microbiology, Immunology, and Molecular Genetics, University of California at Los Angeles, Los Angeles, California 90095 1747, USA
    Leuk Lymphoma 49:1982-94. 2008
  8. ncbi request reprint Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis
    Mario I Vega
    Department of Microbiology, Immunology and Molecular Genetics, University of California, 10833 Le Conte Avenue, A2 060 CHS, Los Angeles, CA 90095, USA
    Oncogene 24:8114-27. 2005
  9. pmc Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells
    Stavroula Baritaki
    Department of Microbiology, Immunology, and Molecular Genetics, Division of Surgical Oncology, David Geffen School of Medicine, University of California Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
    J Immunol 180:6199-210. 2008
  10. ncbi request reprint Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy
    Ali R Jazirehi
    Department of Microbiology, Immunology, and Molecular Genetics, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90024, USA
    Cancer Res 67:1270-81. 2007

Detail Information

Publications23

  1. pmc Therapeutic implications of targeting the PI3Kinase/AKT/mTOR signaling module in melanoma therapy
    Ali R Jazirehi
    Department of Surgery, Division of Surgical Oncology, and The Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, University of California at Los Angeles Los Angeles, CA, USA
    Am J Cancer Res 2:178-91. 2012
    ..This review summarizes the current knowledge on this module, its cross-talk with other major cell survival pathways and its targeted inhibition for therapeutic purposes in melanoma...
  2. pmc Proteasome inhibition blocks NF-κB and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLs
    Ali R Jazirehi
    Department of Surgery and the Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, University of California at Los Angeles, Los Angeles, CA 90095, USA
    Mol Cancer Ther 11:1332-41. 2012
    ..These findings suggest that proteasome inhibition in immune resistant tumors can restore proapoptotic signaling and improve tumor antigen expression...
  3. ncbi request reprint Novel approaches to modulate apoptosis resistance: basic and clinical implications in the treatment of chronic lymphocytic leukemia (CLL)
    Aisha Masood
    The Tisch Cancer Institute, Bone Marrow Transplant, Mount Sinai School of Medicine, NY, NY 10029, USA
    Curr Drug Deliv 9:30-40. 2012
    ..We further discuss the therapeutic options, focusing mainly on targeted therapy using novel agents. Finally, we suggest future directions for treatment that utilize the understanding of the disease biology...
  4. doi request reprint Development of rituximab-resistant B-NHL clones: an in vitro model for studying tumor resistance to monoclonal antibody-mediated immunotherapy
    Ali R Jazirehi
    Department of Surgery, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
    Methods Mol Biol 731:407-19. 2011
    ..The development of RR clones provides a paradigm for studying resistance by other anticancer monoclonal antibodies in various tumor models...
  5. doi request reprint Molecular mechanism of MART-1+/A*0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interaction
    Ali R Jazirehi
    Department of Surgery, Molecular and Medical Pharmacology, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, California, USA
    Cancer Res 71:1406-17. 2011
    ..Though unresponsive to CTL, our results argue that resistant cells can be resensitized to immunotherapy with coadministration of targeted inhibitors to antiapoptotic survival pathways...
  6. doi request reprint Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy
    Ali R Jazirehi
    Department of Surgery, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, California, USA
    Anticancer Drugs 21:805-13. 2010
    ..Herein I review epigenetic modifications, discuss the various mechanisms of HDACi-induced effects, in particular modulation of expression of apoptosis-associated gene products, and highlight SAHA and its antitumor functions...
  7. doi request reprint The NF-kappaB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs
    Mario I Vega
    Department of Microbiology, Immunology, and Molecular Genetics, University of California at Los Angeles, Los Angeles, California 90095 1747, USA
    Leuk Lymphoma 49:1982-94. 2008
    ..These findings offer novel potential therapeutic applications in the reversal of rituximab/drug resistant AIDS-derived B-NHL...
  8. ncbi request reprint Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis
    Mario I Vega
    Department of Microbiology, Immunology and Molecular Genetics, University of California, 10833 Le Conte Avenue, A2 060 CHS, Los Angeles, CA 90095, USA
    Oncogene 24:8114-27. 2005
    ..These findings provide a novel mechanism of rituximab-mediated activity by sensitizing NHL cells to Fas-induced apoptosis...
  9. pmc Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells
    Stavroula Baritaki
    Department of Microbiology, Immunology, and Molecular Genetics, Division of Surgical Oncology, David Geffen School of Medicine, University of California Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
    J Immunol 180:6199-210. 2008
    ..The findings also suggest the therapeutic application of subtoxic NPI-0052 concentrations in combination with TRAIL/agonist DR4/DR5 mAbs in the treatment of TRAIL-resistant tumors...
  10. ncbi request reprint Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy
    Ali R Jazirehi
    Department of Microbiology, Immunology, and Molecular Genetics, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90024, USA
    Cancer Res 67:1270-81. 2007
    ..The findings also identify intracellular targets for potential molecular therapeutic intervention to increase treatment efficacy. The significance and potential clinical relevance of the findings are discussed...
  11. ncbi request reprint Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis
    Ali R Jazirehi
    Department of Microbiology, Immunology, and Molecular Genetics, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA 90095, USA
    Cancer Res 65:264-76. 2005
    ..These findings reveal a novel pathway mediated by rituximab through Raf-1 kinase inhibitor protein induction that negatively regulates the constitutive NF-kappaB pathway and chemosensitization of the NHL B-cells...
  12. doi request reprint Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions
    Mario I Vega
    Department of Microbiology, Immunology, and Molecular Genetics, Jonsson Comprehensive Cancer, David Geffen School of Medicine, University of California, Los Angeles, California 90095 1747, USA
    Clin Cancer Res 15:6582-94. 2009
    ..This study examined the role of Fc-FcR interactions in rituximab-induced signaling using rituximab (Fab')(2) fragments as well as rituximab devoid of the CH2 Fc-binding domain (CH2(-))...
  13. ncbi request reprint Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin's lymphoma cell line via inhibition of NF-kappa B activity: role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectively
    Mario I Vega
    Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA 90095, USA
    J Immunol 175:2174-83. 2005
    ..The potential clinical significance of these findings is discussed...
  14. ncbi request reprint Inhibition of the transcription factor Yin Yang 1 activity by S-nitrosation
    Fumiya Hongo
    Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine and Jonsson Comprehensive Cancer Center at the University of California, Los Angeles, USA
    Biochem Biophys Res Commun 336:692-701. 2005
    ..Altogether, these findings reveal that NO inhibits YY1 DNA-binding activity through S-nitrosation and consequently results in upregulation of Fas expression and tumor cell sensitization to Fas-induced apoptosis...
  15. ncbi request reprint Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis
    Ali R Jazirehi
    Department of Microbiology, Immunology and Molecular Genetics and Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90095, USA
    Mol Cancer Ther 3:71-84. 2004
    ....
  16. ncbi request reprint Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis
    Ali R Jazirehi
    Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA 90095, USA
    Mol Cancer Ther 2:1183-93. 2003
    ..The potential therapeutic significance of these findings is discussed...
  17. ncbi request reprint Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention
    Ali R Jazirehi
    Department of Microbiology, Immunology and Molecular Genetics, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA 90095 1747, USA
    Oncogene 24:2121-43. 2005
    ..Studies presented herein also reveal several intracellular targets modified by rituximab, which can be exploited for therapeutic and prognostic purposes in the treatment of patients with rituximab- and drug-refractory NHL...
  18. pmc Pioneer factor interactions and unmethylated CpG dinucleotides mark silent tissue-specific enhancers in embryonic stem cells
    Jian Xu
    Howard Hughes Medical Institute, Molecular Biology Institute, University of California, Los Angeles, CA 90095, USA
    Proc Natl Acad Sci U S A 104:12377-82. 2007
    ..The enhancer marks may therefore represent important features of the pluripotent state...
  19. ncbi request reprint Raf-1 kinase inhibitor protein: structure, function, regulation of cell signaling, and pivotal role in apoptosis
    Golaun Odabaei
    Department of Microbiology, Immunology, and Molecular Genetics, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, California 90095, USA
    Adv Cancer Res 91:169-200. 2004
    ..Also, induction of RKIP by drugs or anti-receptor antibodies sensitizes cancer cells to drug-induced apoptosis. In this review, we discuss the discovery, structure, function, and significance of RKIP in cancer...
  20. ncbi request reprint Histone deacetylase inhibitor sensitizes apoptosis-resistant melanomas to cytotoxic human T lymphocytes through regulation of TRAIL/DR5 pathway
    Ali R Jazirehi
    Department of Surgery, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095
    J Immunol 192:3981-9. 2014
    ..These preclinical findings suggest that exposure to this chromatin remodeling drug of immune-resistant melanomas can skew toward an intracellular proapoptotic milieu, increase DR expression, and overcome acquired immune resistance. ..
  21. pmc T cell receptor (TCR)-transgenic CD8 lymphocytes rendered insensitive to transforming growth factor beta (TGFβ) signaling mediate superior tumor regression in an animal model of adoptive cell therapy
    Jon G Quatromoni
    Department of Surgery, University of California, Los Angeles, CA 90095, USA
    J Transl Med 10:127. 2012
    ..These results support efforts to incorporate this DN receptor in clinical trials of adoptive cell therapy for cancer...
  22. pmc Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: basic and clinical aspects
    Mohammad A Shahshahan
    Department of Surgery and the Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, University of California Los Angeles, CA 90095, USA
    Am J Cancer Res 1:913-24. 2011
    ..We further discuss the potential use of bortezomib in the treatment of metastatic melanoma...
  23. ncbi request reprint Rituximab-mediated sensitization of B-non-Hodgkin's lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine, and vinorelbine
    Christos Emmanouilides
    Division of Oncology, Jonsson Comprehensive Cancer Center, UCLA School of Medicine, University of California, Los Angeles, CA 90095 1747, USA
    Cancer Biother Radiopharm 17:621-30. 2002
    ..These findings suggest the potential clinical application of combination treatments of rituximab and paclitaxel, gemcitabine or vinorelbine in the treatment of drug/rituximab refractory non-Hodgkin's lymphoma...